---
run_id: halo-evidence-vs-diagnosis-validation-v7-famous-sources-supplied-05
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: famous_sources_supplied
run_number: 5
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 502
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no claims, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: a8f837584b6b87efa42fb92f178885d67f9a6373379ee1ede9671b0a54d4d2f8
condition_packet_sha256: a8f837584b6b87efa42fb92f178885d67f9a6373379ee1ede9671b0a54d4d2f8
output_file: model-outputs/famous_sources_supplied-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `famous_sources_supplied`, run 5 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 502, on the frozen condition packet.

## Output

**Recommendation**
You should recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is a classic example of the **Halo Effect**: leadership is attributing a rise in revenue to product-market fit when the evidence suggests the growth is driven by sales tactics (short-term discounts) rather than product value.

The data indicates a severe gap between "champion" usage and "front-line" utility. A 31% retention rate among actual reviewers is a failure of the core value proposition, not a training issue. Furthermore, the abandonment in state-regulated insurance accounts reveals a "Job to be Done" that Review Assist is currently failing: the need for *auditable* triage.

Scaling now (Option 1) would be "scaling a leaky bucket," committing heavy resources to a product that front-line users are rejecting. Narrowing the focus to regulated workflows (Option 3) is a premature pivot; you do not yet know if the "explainability" problem is a solvable technical hurdle or a fundamental flaw in the product's logic. The evidence pass is the only path that replaces vanity metrics (NRR from discounts) with validated learning (segment-specific behavior and auditor-test results).

**The Strongest Reason Against It**
The primary risk is **political and temporal**. The board is currently enamored with the "upbeat story" and the revenue bump. Recommending a pause on discounts and a period of instrumentation may be perceived by the CEO and Sales leadership as a lack of confidence or a "momentum killer" exactly twelve days before the budget is locked. It risks trading a perceived (though fragile) win for a period of uncertainty.

**Observable Evidence That Would Change My Mind**
I would shift my recommendation to "Scale Broadly" if the instrumentation reveals that the 31% of front-line reviewers who *did* stay are experiencing a "quantum leap" in productivity (e.g., reducing triage time by >50%) and that their retention is independent of the strategic-feature pitch. If the "power users" are not just playing with the tool but are fundamentally transforming their workflow in a way that is scalable without the "explainability" requirement, the risk of scaling becomes acceptable.
